New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
07:29 EDTISISIsis Pharmaceuticals price target lowered to $55 from $63 at Stifel
Stifel cut its price target on ISIS after updated P2 ISIS-SMNRx data in Type-1 spinal muscular atrophy showed two patients in the trial experienced an event. The firm is not surprised by this development but believes it reinforces the risk of conducting such trials. Stifel keeps a Buy rating on the shares.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
17:31 EDTISISIsis Pharmaceuticals cuts stake in Regulus to 5.57%
Subscribe for More Information
July 29, 2015
17:13 EDTISISIsis announces publication of Phase 2 clinical results from volanesorsen study
Isis Pharmaceuticals and Akcea Therapeutics, its wholly owned subsidiary, announced that the New England Journal of Medicine has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen, formerly ISIS-APOCIIIRx, in patients with very high to severely high triglycerides. This publication follows the December 2014 publication in the New England Journal of Medicine of the positive Phase 2 results from a clinical study of volanesorsen in patients with familial chylomicronemia syndrome. Volanesorsen is part of Isis' lipid franchise, which is being developed and commercialized by Akcea Therapeutics.
July 27, 2015
10:40 EDTISISIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
07:07 EDTISISIsis Pharmaceuticals announces results from ISIS-TTRRx study
Subscribe for More Information
July 22, 2015
19:26 EDTISISIsis Pharmaceuticals announces positive clinical data of ISIS-APO(a)Rx published
Subscribe for More Information
July 21, 2015
07:13 EDTISISIsis Pharmaceuticals initiates Phase 1/2a clinical study of ISIS-HTT Rx
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use